Japan· JP-1179024F3083
ゾテピン
A zotepine product containing ゾテピン, registered in Japan by 高田製薬, on the national reimbursement list. The same ATC class is registered in 2 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Zotepine is registered in 2 of 19 countries.
Countries holding a registration under ATC N05AX11 (zotepine), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
Zotepine · ATC N05AX11
2 / 19 countries
- Japan
- United Kingdom
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- ゾテピン
- Manufacturer
- 高田製薬
- Country
- Japan (JP)
- ATC code
- N05AX11
- ATC class
- Zotepine
- Defined daily dose
- 0.2 g, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under N05AX11
Zotepine, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/11aaac1c-c000-4c2d-8d60-55dbe55a151e GET /v1/drugs/11aaac1c-c000-4c2d-8d60-55dbe55a151e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "１００ｍｇ１錠",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "1179024F3083",
"category": "内用薬",
"price_yen": 66.3,
"generic_name": "ゾテピン",
"product_name_jp": null,
"therapeutic_class": "1179",
"transitional_expiry": "R9.3.31まで"
}See everything about zotepine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.